製品名:4-Phthalimidobutyraldehyde

IUPAC Name:4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butanal

CAS番号:3598-60-5
分子式:C12H11NO3
純度:95%
カタログ番号:CM193099
分子量:217.22

包装単位 有効在庫 価格(USD) 数量
CM193099-250mg in stock ȷǕȦ
CM193099-1g in stock ȌDzƤ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:3598-60-5
分子式:C12H11NO3
融点:-
SMILESコード:O=CCCCN1C(=O)C2=C(C=CC=C2)C1=O
密度:
カタログ番号:CM193099
分子量:217.22
沸点:373.9°C at 760 mmHg
MDL番号:MFCD00454178
保管方法:Store at 2-8°C.

Category Infos

Column Infos

Mavorixafor
X4 Pharmaceuticals’ lead product candidate, Mavorixafor (X4P-001) has reached a significant milestone with the submission of a New Drug Application (NDA) to the U.S. FDA for the treatment of WHIM Syndrome on September 5. This marks an important step forward in the regulatory approval process for Mavorixafor and highlights its potential as a promising therapy for patients with WHIM Syndrome.
WHIM syndrome was named after four symptoms: Warts, Hypogammaglobulinemia, Infections, Myelokathexis. WHIM syndrome is a rare and difficult-to-diagnose primary immunodeficiency in which the body’s immune system does not function properly and has trouble fighting infections, especially respiratory, ear, and skin infections.
Mavorixafor is an investigational small-molecule CXCR4 antagonist. It allosterically blocks the overstimulation of the CXCL12/CXCR4 pathway, having the potential to improve immune cell trafficking and immunosurveillance. Mavorixafor was designated orphan drug status by both the U.S. and the EU, and previously granted Fast Track Designation and Breakthrough Therapy Designation by the FDA.

Related Products